HRP20120228T1 - Kladribinski režim za liječenje multiple skleroze - Google Patents

Kladribinski režim za liječenje multiple skleroze Download PDF

Info

Publication number
HRP20120228T1
HRP20120228T1 HR20120228T HRP20120228T HRP20120228T1 HR P20120228 T1 HRP20120228 T1 HR P20120228T1 HR 20120228 T HR20120228 T HR 20120228T HR P20120228 T HRP20120228 T HR P20120228T HR P20120228 T1 HRP20120228 T1 HR P20120228T1
Authority
HR
Croatia
Prior art keywords
cladribine
period
months
pharmaceutical formulation
administered
Prior art date
Application number
HR20120228T
Other languages
English (en)
Croatian (hr)
Inventor
De Luca Giampiero
Ythier Arnaud
Munafo Alain
Lopez-Bresnahan Maria
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120228(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of HRP20120228T1 publication Critical patent/HRP20120228T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HR20120228T 2004-12-22 2005-12-20 Kladribinski režim za liječenje multiple skleroze HRP20120228T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
HRP20120228T1 true HRP20120228T1 (hr) 2012-04-30

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120228T HRP20120228T1 (hr) 2004-12-22 2005-12-20 Kladribinski režim za liječenje multiple skleroze

Country Status (25)

Country Link
US (2) US7713947B2 (de)
EP (7) EP2275110B1 (de)
JP (7) JP5795456B2 (de)
KR (1) KR20070091662A (de)
AR (1) AR052830A1 (de)
AU (2) AU2005318190B2 (de)
BR (1) BRPI0517132B8 (de)
CA (2) CA3087419C (de)
CY (3) CY1112614T1 (de)
DK (3) DK2805723T3 (de)
EA (1) EA015799B1 (de)
ES (2) ES3007339T3 (de)
FI (1) FI4070800T3 (de)
FR (1) FR18C1008I2 (de)
HR (1) HRP20120228T1 (de)
HU (3) HUE059133T2 (de)
IL (2) IL183930A0 (de)
LT (3) LT4070800T (de)
LU (1) LUC00064I2 (de)
MX (1) MX2007007610A (de)
NO (1) NO20073813L (de)
PL (4) PL1827461T3 (de)
SG (1) SG160391A1 (de)
SI (3) SI2805723T1 (de)
WO (1) WO2006067141A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275110B1 (de) 2004-12-22 2013-07-10 Merck Serono SA Cladribin Dosierschema zur Behandlung von multipler Sklerose
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (de) 2010-09-08 2012-03-14 Merck Serono S.A. Orale Verabreichung von Nukleosidmonophosphaten
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) * 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (de) 1994-12-22 2002-09-04 Ortho Pharmaceutical Corporation Lösliche arzneizusammensetzungen enthaltend 2-chloro-2'-deoxyadenosine
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (de) 2002-09-25 2013-05-01 Brigham Young University Verfahren zur herstellung von 2-halogen-2-desoxyadenosinverbindungen aus 2-desoxyguanosin
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (en) * 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
DK2272503T3 (da) 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
WO2004087100A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
EP2275110B1 (de) 2004-12-22 2013-07-10 Merck Serono SA Cladribin Dosierschema zur Behandlung von multipler Sklerose
WO2007135172A2 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
LUC00064I1 (de) 2018-02-14
EP4070800A1 (de) 2022-10-12
IL212421A (en) 2014-01-30
EP2805723A1 (de) 2014-11-26
EP2275110A2 (de) 2011-01-19
FR18C1008I1 (de) 2018-03-30
JP2020193206A (ja) 2020-12-03
JP2016138128A (ja) 2016-08-04
JP5795456B2 (ja) 2015-10-14
EP2805723B1 (de) 2018-01-17
IL183930A0 (en) 2007-10-31
HUE059133T2 (hu) 2022-10-28
EP2275110B1 (de) 2013-07-10
JP5908863B2 (ja) 2016-04-26
PL3332789T3 (pl) 2022-08-22
JP6290962B2 (ja) 2018-03-07
EP2275110A3 (de) 2011-04-27
FR18C1008I2 (fr) 2019-03-01
JP6092945B2 (ja) 2017-03-08
ES3007339T3 (en) 2025-03-19
CY2018006I1 (el) 2018-06-27
CY2018006I2 (el) 2018-06-27
ES2921858T3 (es) 2022-09-01
LT4070800T (lt) 2025-01-10
EP4523753A2 (de) 2025-03-19
SG160391A1 (en) 2010-04-29
EP4070800B1 (de) 2024-10-16
PL1827461T3 (pl) 2012-07-31
AU2005318190B2 (en) 2010-11-25
US8377903B2 (en) 2013-02-19
EP3332789A1 (de) 2018-06-13
EP2263678A2 (de) 2010-12-22
AU2005318190A1 (en) 2006-06-29
CA3087419C (en) 2023-03-07
LTC2805723I2 (lt) 2022-04-25
EP2263678B1 (de) 2014-06-11
BRPI0517132B1 (pt) 2020-02-18
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
JP6430554B2 (ja) 2018-11-28
EA015799B1 (ru) 2011-12-30
CA2588966A1 (en) 2006-06-29
US20100203017A1 (en) 2010-08-12
PL2805723T3 (pl) 2018-04-30
EP1827461B1 (de) 2012-02-29
LT3332789T (lt) 2022-07-25
EA200701221A1 (ru) 2008-02-28
CY1119790T1 (el) 2018-06-27
CY1112614T1 (el) 2016-02-10
EP2263678A3 (de) 2011-04-27
CA3087419A1 (en) 2006-06-29
WO2006067141A1 (en) 2006-06-29
AU2011200768B2 (en) 2012-09-13
NO20073813L (no) 2007-09-21
JP2017101061A (ja) 2017-06-08
HUS1800009I1 (hu) 2018-05-02
SI3332789T1 (sl) 2022-08-31
MX2007007610A (es) 2007-08-03
KR20070091662A (ko) 2007-09-11
DK2805723T3 (da) 2018-01-29
EP3332789B1 (de) 2022-04-06
JP2008524313A (ja) 2008-07-10
EP4523753A3 (de) 2025-05-28
EP1827461A1 (de) 2007-09-05
US20090081163A1 (en) 2009-03-26
JP2015180685A (ja) 2015-10-15
JP2018165271A (ja) 2018-10-25
US7713947B2 (en) 2010-05-11
IL212421A0 (en) 2011-06-30
JP2013216664A (ja) 2013-10-24
BRPI0517132A (pt) 2008-09-30
HUE070333T2 (hu) 2025-05-28
LUC00064I2 (de) 2018-03-28
SI2805723T1 (en) 2018-02-28
BRPI0517132B8 (pt) 2021-05-25
FI4070800T3 (fi) 2025-01-14
SI4070800T1 (sl) 2025-03-31
AR052830A1 (es) 2007-04-04
LTPA2018503I1 (lt) 2018-03-12
CA2588966C (en) 2020-07-21
AU2011200768A1 (en) 2011-03-17
PL4070800T3 (pl) 2025-03-10

Similar Documents

Publication Publication Date Title
HRP20110198T1 (hr) Indikacija doziranja progesterona u liječenju traumatske ozljede mozga
HRP20120147T1 (hr) Titracija tapentadola
HRP20120382T1 (hr) Kombinacija davanja interferona-beta i kladribina za liječenje multiple skleroze
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
HRP20120228T1 (hr) Kladribinski režim za liječenje multiple skleroze
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
AU4451101A (en) Method and compositions for preventing hormone induced adverse effects
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
WO2007047327A3 (en) Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
JP2002523370A5 (de)
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
UA102187C2 (ru) Фармацевтическая композиция для пероральной доставки дииндолилметана
WO2006068768A3 (en) Methods and compositions for treating conditions
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
HRP20130071T1 (hr) Poboljšani testosteron u gelu i naäśin primjene
CA2563058C (en) Supportive treatment of liver disease
JP2005525329A5 (de)
MX2007004120A (es) Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
ME02149B (me) FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE
JP2009539916A5 (de)
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
PL1694320T3 (pl) Zastosowanie kompozycji zawierających kwas oleanolowy i kwas ursolowy do wytwarzania leku do leczenia nadwrażliwości i nadreaktywności
ES2172179T3 (es) Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.